Magrath George

CEO George Magrath buys 100,000 shares (100.0K) of Opus Genetics at $0.98 on 2024-12-26, raising stake to 599,150 shares.

George Magrath, Chief Executive Officer of Opus Genetics, purchased 100,000 shares at $0.98 on 2024-12-26, a 20.0% increase in his holdings. The stock currently trades at $1.12, placing the transaction price 17% below the 52-week high of $1.35. This is his third open-market purchase at IRD in roughly six weeks, following buys on 2024-11-15 and 2024-11-18. However, the company's fundamentals present significant headwinds: annual revenue contracted 52.2% year-over-year to $3.9M in the latest quarter, the company posted net income of $-7.5M on an unprofitable basis, and the market cap is $35.4M. Magrath's cross-ticker track record shows 4 prior buys with an average 90-day return of -22.6% and a 0.00% win rate, though same-ticker outcomes at IRD remain partially unmeasurable. The accumulation pattern warrants examination given the deteriorating revenue trajectory and persistent losses.

CEO George Magrath purchased 100,000 shares (100.0K shares) for $101,157.83 across 2 transactions at Opus Genetics (IRD), raising stake 25.4%.

George Magrath, CEO of Opus Genetics, executed 2 separate purchases totaling 100,000 shares for $101,157.83 on November 15 and November 18, 2024, increasing his holdings from 392,950 to 492,950 shares (+25.4%). The transactions occurred at an average price of $1.01, above the current market price of $0.88 as of November 19—a premium of roughly 15% to today's price. This substantial share acquisition by the Chief Executive Officer is notable given the company's material operational stress: revenue declined 52.2% year-over-year, the company reported a net loss of $7,526,000.00 in its latest quarter, and annual net income was negative. The timing and magnitude of this insider purchase, combined with the company's recent IPO status (19 trading days) and ongoing unprofitability, warrant careful attention to understand the CEO's view of valuation and company trajectory.